Additional file 1 of Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-up ...
Additional file 1. Supplementary Table S1. List of Rx-Risk-V comorbidity categories with corresponding medicine groups and Anatomical Therapeutic Chemical (ATC), and ATC codes of medications dispensed to patients included in the Opera-C study. Supplementary Table 2. Prevalence of comorbidity categor...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Text |
Language: | unknown |
Published: |
figshare
2022
|
Subjects: | |
Online Access: | https://dx.doi.org/10.6084/m9.figshare.20296534 https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_of_Hepatitis_C_treatment_outcomes_for_Australian_First_Nations_Peoples_equivalent_SVR_rate_but_higher_rates_of_loss_to_follow-up/20296534 |
Summary: | Additional file 1. Supplementary Table S1. List of Rx-Risk-V comorbidity categories with corresponding medicine groups and Anatomical Therapeutic Chemical (ATC), and ATC codes of medications dispensed to patients included in the Opera-C study. Supplementary Table 2. Prevalence of comorbidity categories included in the Rx-Risk-V according for First Nations Peoples and non-Indigenous Australians. Supplementary Table 3. Logistic regression analysis of factors associated with loss to follow-up among First Nations Peoples. ... |
---|